Equities research analysts predict that Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) will announce sales of $58.03 million for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Vanda Pharmaceuticals’ earnings, with estimates ranging from $56.40 million to $60.00 million. Vanda Pharmaceuticals reported sales of $49.14 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 18.1%. The company is scheduled to report its next earnings report on Wednesday, November 6th.
According to Zacks, analysts expect that Vanda Pharmaceuticals will report full-year sales of $224.33 million for the current fiscal year, with estimates ranging from $220.10 million to $229.00 million. For the next financial year, analysts expect that the company will post sales of $274.63 million, with estimates ranging from $247.10 million to $326.80 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Vanda Pharmaceuticals.
Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, July 31st. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.24. Vanda Pharmaceuticals had a return on equity of 10.23% and a net margin of 13.61%. The business had revenue of $59.06 million during the quarter, compared to the consensus estimate of $54.19 million. During the same period last year, the company earned $0.15 EPS. The company’s revenue for the quarter was up 24.7% on a year-over-year basis.
A number of research firms have recently weighed in on VNDA. Citigroup upgraded Vanda Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $19.00 price target for the company in a report on Thursday, August 1st. Oppenheimer set a $18.00 price target on Vanda Pharmaceuticals and gave the stock a “hold” rating in a report on Sunday, May 5th. Zacks Investment Research upgraded Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a report on Friday, August 2nd. ValuEngine upgraded Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $17.00 price target on shares of Vanda Pharmaceuticals in a report on Wednesday, July 31st. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $26.57.
In related news, CEO Mihael Hristos Polymeropoulos sold 72,872 shares of the firm’s stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $15.34, for a total transaction of $1,117,856.48. Following the completion of the transaction, the chief executive officer now directly owns 1,276,343 shares in the company, valued at approximately $19,579,101.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Timothy Williams sold 2,575 shares of the firm’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $14.69, for a total value of $37,826.75. Following the transaction, the senior vice president now owns 57,425 shares of the company’s stock, valued at $843,573.25. The disclosure for this sale can be found here. Corporate insiders own 8.20% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the stock. Comerica Bank boosted its holdings in Vanda Pharmaceuticals by 1.4% during the 1st quarter. Comerica Bank now owns 51,842 shares of the biopharmaceutical company’s stock valued at $928,000 after acquiring an additional 725 shares during the period. Piedmont Investment Advisors Inc. boosted its holdings in Vanda Pharmaceuticals by 5.9% during the 1st quarter. Piedmont Investment Advisors Inc. now owns 13,198 shares of the biopharmaceutical company’s stock valued at $243,000 after acquiring an additional 737 shares during the period. United Services Automobile Association boosted its holdings in Vanda Pharmaceuticals by 5.8% during the 2nd quarter. United Services Automobile Association now owns 14,544 shares of the biopharmaceutical company’s stock valued at $205,000 after acquiring an additional 792 shares during the period. Rhumbline Advisers boosted its holdings in Vanda Pharmaceuticals by 0.6% during the 1st quarter. Rhumbline Advisers now owns 149,949 shares of the biopharmaceutical company’s stock valued at $2,759,000 after acquiring an additional 832 shares during the period. Finally, Arizona State Retirement System boosted its holdings in Vanda Pharmaceuticals by 1.2% during the 2nd quarter. Arizona State Retirement System now owns 82,158 shares of the biopharmaceutical company’s stock valued at $1,158,000 after acquiring an additional 949 shares during the period. Institutional investors own 99.33% of the company’s stock.
Shares of VNDA traded up $0.28 during midday trading on Tuesday, reaching $15.19. The company had a trading volume of 525,000 shares, compared to its average volume of 893,224. Vanda Pharmaceuticals has a 1-year low of $11.83 and a 1-year high of $33.44. The stock has a market cap of $794.31 million, a PE ratio of 31.65 and a beta of 0.38. The firm has a 50 day simple moving average of $13.91 and a 200-day simple moving average of $16.65.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
See Also: Stop Order Uses For Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.